![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ANXA5 |
Gene summary for ANXA5 |
![]() |
Gene information | Species | Human | Gene symbol | ANXA5 | Gene ID | 308 |
Gene name | annexin A5 | |
Gene Alias | ANX5 | |
Cytomap | 4q27 | |
Gene Type | protein-coding | GO ID | GO:0006915 | UniProtAcc | P08758 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
308 | ANXA5 | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 1.76e-03 | -4.24e-01 | 0.1602 |
308 | ANXA5 | GSM5353232_PA_PR5249_T1_S3_L001 | Human | Prostate | Tumor | 5.22e-05 | -9.18e-01 | 0.1439 |
308 | ANXA5 | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 2.69e-06 | -4.10e-01 | 0.1575 |
308 | ANXA5 | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 1.04e-16 | -3.85e-01 | 0.1545 |
308 | ANXA5 | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 2.64e-11 | -3.91e-01 | 0.1569 |
308 | ANXA5 | GSM5353247_PA_PR5269_3_S27_L002 | Human | Prostate | Tumor | 2.23e-02 | -9.18e-01 | 0.1532 |
308 | ANXA5 | P1_S1_AK | Human | Skin | AK | 9.78e-06 | -4.53e-01 | -0.3399 |
308 | ANXA5 | P2_S3_AK | Human | Skin | AK | 1.90e-07 | -4.81e-01 | -0.3287 |
308 | ANXA5 | P3_S6_AK | Human | Skin | AK | 3.71e-09 | -5.10e-01 | -0.3256 |
308 | ANXA5 | P4_S8_cSCC | Human | Skin | cSCC | 3.32e-12 | -3.99e-01 | -0.3095 |
308 | ANXA5 | P5_S10_cSCC | Human | Skin | cSCC | 2.20e-16 | 1.76e-02 | -0.299 |
308 | ANXA5 | P1_cSCC | Human | Skin | cSCC | 2.72e-10 | 9.75e-01 | 0.0292 |
308 | ANXA5 | P4_cSCC | Human | Skin | cSCC | 2.85e-07 | 7.59e-01 | -0.00290000000000005 |
308 | ANXA5 | P10_cSCC | Human | Skin | cSCC | 1.88e-35 | 1.79e+00 | 0.1017 |
308 | ANXA5 | cSCC_p1 | Human | Skin | cSCC | 9.63e-11 | -5.21e-01 | -0.1916 |
308 | ANXA5 | cSCC_p10 | Human | Skin | cSCC | 2.60e-15 | -6.37e-01 | -0.2095 |
308 | ANXA5 | cSCC_p11 | Human | Skin | cSCC | 2.07e-16 | -6.73e-01 | -0.2102 |
308 | ANXA5 | cSCC_p3 | Human | Skin | cSCC | 4.67e-15 | -6.68e-01 | -0.2085 |
308 | ANXA5 | cSCC_p4 | Human | Skin | cSCC | 5.64e-21 | -7.11e-01 | -0.2022 |
308 | ANXA5 | cSCC_p6 | Human | Skin | cSCC | 5.48e-18 | -6.98e-01 | -0.1989 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00420609 | Breast | Precancer | wound healing | 48/1080 | 422/18723 | 5.48e-06 | 1.63e-04 | 48 |
GO:00508789 | Breast | Precancer | regulation of body fluid levels | 40/1080 | 379/18723 | 1.68e-04 | 2.77e-03 | 40 |
GO:00075995 | Breast | Precancer | hemostasis | 24/1080 | 222/18723 | 2.31e-03 | 2.15e-02 | 24 |
GO:00075965 | Breast | Precancer | blood coagulation | 23/1080 | 217/18723 | 3.61e-03 | 2.98e-02 | 23 |
GO:00508175 | Breast | Precancer | coagulation | 23/1080 | 222/18723 | 4.78e-03 | 3.64e-02 | 23 |
GO:004206014 | Breast | IDC | wound healing | 55/1434 | 422/18723 | 7.27e-05 | 1.45e-03 | 55 |
GO:005087813 | Breast | IDC | regulation of body fluid levels | 50/1434 | 379/18723 | 1.12e-04 | 2.10e-03 | 50 |
GO:005087823 | Breast | DCIS | regulation of body fluid levels | 50/1390 | 379/18723 | 5.17e-05 | 1.06e-03 | 50 |
GO:004206024 | Breast | DCIS | wound healing | 54/1390 | 422/18723 | 6.09e-05 | 1.22e-03 | 54 |
GO:004206010 | Cervix | CC | wound healing | 109/2311 | 422/18723 | 1.84e-14 | 1.57e-11 | 109 |
GO:005087810 | Cervix | CC | regulation of body fluid levels | 78/2311 | 379/18723 | 3.20e-06 | 8.77e-05 | 78 |
GO:00508176 | Cervix | CC | coagulation | 45/2311 | 222/18723 | 5.08e-04 | 4.94e-03 | 45 |
GO:00075966 | Cervix | CC | blood coagulation | 44/2311 | 217/18723 | 5.78e-04 | 5.52e-03 | 44 |
GO:00075996 | Cervix | CC | hemostasis | 44/2311 | 222/18723 | 9.47e-04 | 7.95e-03 | 44 |
GO:004206025 | Cervix | N_HPV | wound healing | 28/534 | 422/18723 | 3.37e-05 | 8.58e-04 | 28 |
GO:005087824 | Cervix | N_HPV | regulation of body fluid levels | 22/534 | 379/18723 | 1.37e-03 | 1.49e-02 | 22 |
GO:005081721 | Cervix | N_HPV | coagulation | 14/534 | 222/18723 | 4.76e-03 | 3.52e-02 | 14 |
GO:004206016 | Endometrium | AEH | wound healing | 91/2100 | 422/18723 | 4.85e-10 | 4.61e-08 | 91 |
GO:00075967 | Endometrium | AEH | blood coagulation | 43/2100 | 217/18723 | 1.42e-04 | 1.89e-03 | 43 |
GO:00075997 | Endometrium | AEH | hemostasis | 43/2100 | 222/18723 | 2.39e-04 | 2.86e-03 | 43 |
Page: 1 2 3 4 5 6 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ANXA5 | insertion | Frame_Shift_Ins | novel | c.564_565insG | p.Thr189AspfsTer3 | p.T189Dfs*3 | P08758 | protein_coding | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | ||
ANXA5 | SNV | Missense_Mutation | rs780076315 | c.451N>T | p.Arg151Trp | p.R151W | P08758 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ANXA5 | SNV | Missense_Mutation | c.149N>A | p.Arg50His | p.R50H | P08758 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ANXA5 | SNV | Missense_Mutation | novel | c.278N>T | p.Ala93Val | p.A93V | P08758 | protein_coding | tolerated(0.22) | benign(0.298) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ANXA5 | SNV | Missense_Mutation | rs137877895 | c.605N>A | p.Ser202Asn | p.S202N | P08758 | protein_coding | tolerated(0.22) | probably_damaging(0.939) | TCGA-DM-A285-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ANXA5 | SNV | Missense_Mutation | novel | c.812N>T | p.Arg271Ile | p.R271I | P08758 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ANXA5 | SNV | Missense_Mutation | novel | c.20N>T | p.Gly7Val | p.G7V | P08758 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ANXA5 | SNV | Missense_Mutation | novel | c.870N>T | p.Lys290Asn | p.K290N | P08758 | protein_coding | tolerated(0.14) | probably_damaging(0.964) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
ANXA5 | SNV | Missense_Mutation | novel | c.223N>A | p.Gly75Arg | p.G75R | P08758 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
ANXA5 | SNV | Missense_Mutation | novel | c.85N>G | p.Lys29Glu | p.K29E | P08758 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
308 | ANXA5 | KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER | Diannexin | |||
308 | ANXA5 | KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER | BETA-LAPACHONE | LAPACHONE | 11474117 | |
308 | ANXA5 | KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER | DNR | 11986942 |
Page: 1 |